Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSIP1 | O75475 | 2/20 | 0.53 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CA6 | P23280 | 2/20 | 0.38 |
| ▸ | CA5A | P35218 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1145511 | 0.83 | PIK3CD (0.42) | PSIP1LOXL2CA2CA1CA12 | |
| SCHEMBL5758401 | 0.83 | PIK3CD (0.42) | PSIP1LOXL2CA2CA1CA12 | |
| SCHEMBL2584663 | 0.83 | PSIP1 (0.40) | PSIP1LOXL2CA2CA1CA12 | |
| SCHEMBL20240393 | 0.81 | HTR2A (0.38) | PSIP1CA2CA1CA12CA4 | |
| SCHEMBL12409435 | 0.81 | CA2 (0.57) | PSIP1LOXL2CA2CA1CA12 | |
| Hydrochloric Acid SCHEMBL23144996 | 0.79 | CA2 (0.55) | PSIP1LOXL2CA2CA1CA12 | |
| SCHEMBL2642700 | 0.79 | POLB (0.39) | PSIP1LOXL2CA2CA1CA12 | |
| SCHEMBL3123376 | 0.79 | PSIP1 (0.38) | PSIP1LOXL2CA2CA1CA12 | |
| SCHEMBL12094938 | 0.78 | CA2 (0.43) | PSIP1LOXL2CA2CA1CA12 | |
| SCHEMBL18283328 | 0.77 | P4HTM (0.53) | CA2CA5AMAPTKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3418280-B1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2023-07-12 | — | — | EP | disclosed |
| US-11358967-B2 | Substituted pyrazino[2,3-b]pyrazines and pyrazino[2,3-c]pyridazines as modulators of ROR gamma | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-06-14 | — | — | US | disclosed |
| US-20210171527-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-06-10 | — | — | US | disclosed |
| EP-3405470-B1 | PYRAZINEDIHYDROPYRIMIDINONE OR PYRIDAZINEDIHYDROPYRIMIDINONE COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2020-07-15 | — | — | EP | disclosed |
| US-10450314-B2 | Pteridine derivatives as modulators of ROR gamma | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-10-22 | — | — | US | disclosed |
| EP-3356366-B1 | PTERIDINE DERIVATIVES AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2019-08-28 | — | — | EP | disclosed |
| EP-3131902-B1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2019-06-12 | — | — | EP | disclosed |
| US-20180022749-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2018-01-25 | — | — | US | disclosed |
| US-20180022749-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INT (DE) | 2018-01-25 | — | — | US | disclosed |
| WO-2017127375-A1 | PYRAZINEDIHYDROPYRIMIDINONE OR PYRIDAZINEDIHYDROPYRIMIDINONE COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-07-27 | — | — | WO | disclosed |
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-9242989-B2 | Compounds as modulators of RORγ | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| US-9242989-B2 | Compounds as modulators of RORγ | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| WO-2015160654-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-22 | — | — | WO | disclosed |
| US-20150291607-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-15 | — | — | US | disclosed |
| US-20150291607-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-15 | — | — | US | disclosed |
| US-8338610-B2 | Pyridinyl compounds useful as intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| WO-2010036632-A1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | PSIP1 4704/4885LOXL2 3029/4885CA2 2686/4885 |
| US-20180022749-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | RORB, RORC, RORA | PSIP1 2803/4885LOXL2 3783/4885CA2 2461/4885 |
| US-20210171527-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | RORC, RORB, RORA | PSIP1 2746/4885LOXL2 3785/4885CA2 2453/4885 |
| US-10450314-B2 | Pteridine derivatives as modulators of ROR gamma | RORB, RORC, RORA | PSIP1 2041/4885LOXL2 4486/4885CA2 3321/4885 |
| US-20150291607-A1 | COMPOUNDS AS MODULATORS OF ROR GAMMA | RORB, RORC, RORA | PSIP1 2803/4885LOXL2 3783/4885CA2 2461/4885 |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | CCR1, CCRL2, CCR4 | PSIP1 3366/4885LOXL2 1706/4885CA2 3968/4885 |
| US-11358967-B2 | Substituted pyrazino[2,3-b]pyrazines and pyrazino[2,3-c]pyridazines as modulators of ROR gamma | RORC, RORB, RORA | PSIP1 1758/4885LOXL2 3898/4885CA2 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.